Literature DB >> 24842528

Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes.

P K Bhamidipati1, J F DiPersio2, K Stokerl-Goldstein2, A Rashidi2, F Gao3, G L Uy2, P Westervelt2, R Vij2, M A Schroeder2, C N Abboud2, J W Keller2, T A Fehniger2, R Romee2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24842528     DOI： 10.1038/bmt.2014.108

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  6 in total

1.  A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing.

Authors:  Dolores Grosso; Matthew Carabasi; Joanne Filicko-O'Hara; Margaret Kasner; John L Wagner; Beth Colombe; Patricia Cornett Farley; William O'Hara; Phyllis Flomenberg; Maria Werner-Wasik; Janet Brunner; Bijoyesh Mookerjee; Terry Hyslop; Mark Weiss; Neal Flomenberg
Journal:  Blood       Date:  2011-08-25       Impact factor: 22.113

2.  Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.

Authors:  H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas
Journal:  Transplantation       Date:  1974-10       Impact factor: 4.939

3.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

4.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Authors:  Leo Luznik; Paul V O'Donnell; Heather J Symons; Allen R Chen; M Susan Leffell; Marianna Zahurak; Ted A Gooley; Steve Piantadosi; Michele Kaup; Richard F Ambinder; Carol Ann Huff; William Matsui; Javier Bolaños-Meade; Ivan Borrello; Jonathan D Powell; Elizabeth Harrington; Sandy Warnock; Mary Flowers; Robert A Brodsky; Brenda M Sandmaier; Rainer F Storb; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2008-06       Impact factor: 5.742

5.  Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial.

Authors:  Scott R Solomon; Connie A Sizemore; Melissa Sanacore; Xu Zhang; Stacey Brown; H Kent Holland; Lawrence E Morris; Asad Bashey
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-01       Impact factor: 5.742

6.  Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.

Authors:  Anna Maria Raiola; Alida Dominietto; Anna Ghiso; Carmen Di Grazia; Teresa Lamparelli; Francesca Gualandi; Stefania Bregante; Maria Teresa Van Lint; Simona Geroldi; Silvia Luchetti; Filippo Ballerini; Maurizio Miglino; Riccardo Varaldo; Andrea Bacigalupo
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-29       Impact factor: 5.742
  6 in total
  8 in total

1.  HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment.

Authors:  Joseph Rimando; Michael Slade; John F DiPersio; Peter Westervelt; Feng Gao; Chang Liu; Rizwan Romee
Journal:  Blood Adv       Date:  2018-12-26

Review 2.  Haploidentical vs cord blood transplantation for adults with acute myelogenous leukemia.

Authors:  Melhem Solh
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

3.  The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide.

Authors:  Joseph Rimando; Michael Slade; John F DiPersio; Peter Westervelt; Feng Gao; Chang Liu; Rizwan Romee
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-26       Impact factor: 5.742

4.  Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide.

Authors:  Asad Bashey; Mei-Jie Zhang; Shannon R McCurdy; Andrew St Martin; Trevor Argall; Claudio Anasetti; Stefan O Ciurea; Omotayo Fasan; Sameh Gaballa; Mehdi Hamadani; Pashna Munshi; Monzr M Al Malki; Ryotaro Nakamura; Paul V O'Donnell; Miguel-Angel Perales; Kavita Raj; Rizwan Romee; Scott Rowley; Vanderson Rocha; Rachel B Salit; Melhem Solh; Robert J Soiffer; Ephraim Joseph Fuchs; Mary Eapen
Journal:  J Clin Oncol       Date:  2017-06-23       Impact factor: 44.544

Review 5.  Halfway there: the past, present and future of haploidentical transplantation.

Authors:  M Slade; B Fakhri; B N Savani; R Romee
Journal:  Bone Marrow Transplant       Date:  2016-07-25       Impact factor: 5.483

6.  Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated.

Authors:  Ramzi Abboud; Jesse Keller; Michael Slade; John F DiPersio; Peter Westervelt; Michael P Rettig; Stephanie Meier; Todd A Fehniger; Camille N Abboud; Geoffrey L Uy; Ravi Vij; Kathryn M Trinkaus; Mark A Schroeder; Rizwan Romee
Journal:  Biol Blood Marrow Transplant       Date:  2016-06-16       Impact factor: 5.742

Review 7.  Review of Haploidentical Hematopoietic Cell Transplantation.

Authors:  Mehreen A Khan; Qaiser Bashir; Qamar-Un-Nisa Chaudhry; Parvez Ahmed; Tariq M Satti; Syed K Mahmood
Journal:  J Glob Oncol       Date:  2018-12

Review 8.  Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow-Review of Published Literature.

Authors:  Shatha Farhan; Edward Peres; Nalini Janakiraman
Journal:  Adv Hematol       Date:  2016-03-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.